Despite bringing a significant price reduction, biosimilars might lag in taking over the market of the drugs they copy because of exclusivity policies set up by the owners of brand-name drugs.  A report in Bloomberg Markets yesterday highlights the case of Inflectra, a biosimilar from Pfizer that imitates Johnson & Johnson’s rheumatoid arthritis blockbuster Remicade (infliximab). Despite bringing a price reduction […]